Table 1.
Characteristics of included studies
| Authors, year | Country | Study design | Type of manuscript | Sample size, n | Gender, M, % | Age, years | Disease duration, years | Location of disease (extensive/left sided/ proctitis), n | Severity of disease | Baseline CRP | Prior IM, n, (%) | Concomitant CS, n, (%) | Prior anti-TNFα, n (%) | Prior ≥2 anti-TNFα, n, (%) | Prior VED, n, (%) | Prior TOF, n, (%) | Concomitant IM therapy, n, (%) | Assessment time point, week |
| Fumery M et al,7 2021 | France | R | Full article | 103 | 60.2 | 39.3 (29.1–52.3)b | 7.6 (3.6–12.9)b | 54/43/6 | Moderate | 7.1 (NR)a | 87 (84.5) | 50 (48.5) | 102 (99.0) | 72 (69.9) | 88 (85.4) | 10 (9.71) | 24 (23.3) | 12–16, 26, 52 |
| Chaparro M et al,19 2021 | Spain | P | Full article | 95 | 44.2 | 47 (16)a | NR | 55/37/3 | Moderate | NR | NR | 53 (55.8) | 93 (97.9) | 55 (57.9) | 78 (82.1) | 28 (29.5) | 16 (16.8) | 16, 24, 52 |
| Dalal RS et al,20 2021 | USA | R | Full article | 108 | 43.5 | 39 (30–56)c | 9 (4–16)c | NR/NR/28 | Mild | 3.6 (0.8–12.9)b | 68 (63.0) | 62 (57.4) | 99 (91.7) | 43 (39.8) | NR | NR | 18 (16.7) | 12–16 |
| Amiot A et al,8 2020 | France | P | Full article | 103 | 60.2 | 39.3 (29.1–52.3)c | 7.6 (3.6–12.9)c | 54/43/6 | Moderate | 7.1 (3.1–15.0)c | 85 (82.5) | 50 (48.5) | 102 (99.0) | 72 (69.9) | 88 (85.4) | 10 (9.71) | 24 (23.3) | 12–16 |
| Ochsenkühn T et al,21 2020 | Germany | R | Full article | 19 | 57.9 | 46 (25–81)b | 5 (2–15)b | 11/7/0 | Moderate | NR | NR | 9 (47.4) | 8 (42.1) | NR | 6 (31.6) | NR | 1 (5.26) | 52 |
| Chiappetta MF et al,22 2021 | Italy | R | Full article | 68 | 63.2 | 42 (16–72)b | 8 (NR)b | 41/25/2 | Moderate | NR | NR | 37 (54.4) | 65 (95.6) | 30 (44.1) | 47 (69.1) | NR | 15 (22.1) | 8, 24, 52 |
| Hong S et al,23 2020 | USA | R | Abstract | 19 | 47.4 | 43 (NR)b | 9.6 (NR)b | 10/8/1 | Moderate | 0.48 (0.8)a | 16 (84.2) | NR | 19 (100) | 5 (26.3) | 17 (89.5) | 2 (10.5) | 16 (84.2) | 12, 52 |
| Dalal RS et al,24 2021 | USA | R | Abstract | 81 | 21.0 | 41.7 (11.5)a | 8.6 (NR)a | 22/13/1 | Mild | 1.24 (2.53)a | 28 (34.6) | 23 (28.4) | 34 (42.0) | 17 (21.0) | 34 (42.0) | NR | 8 (9.88) | 12–16, 52 |
| Dalal RS et al,25 2021 | USA | R | Abstract | 108 | 43.5 | 39 (30–56)b | 9 (4–16)b | NR/NR/28 | Mild | 0.36 (0.08–1.29)b | 68 (63.0) | 62 (57.4) | 99 (91.7) | 43 (39.8) | 72 (66.7) | 22 (20.4) | 18 (16.7) | 12–16 |
| Haraikawa M et al,26 2021 | Japan | R | Abstract | 19 | 57.9 | 47.4 (NR)a | NR | NR/NR/NR | Moderate | NR | NR | NR | 6 (31.6) | NR | 11 (57.9) | NR | NR | 8, 24 |
| Yamana Y et al,27 2021 | Japan | R | Abstract | 11 | 27.3 | 40 (24–71)b | NR (2.08–12.7)b | 3/6/0 | NR | NR | NR | NR | 6 (54.5) | NR | NR | NR | NR | 4 |
| Asaeda K et al,28 2021 | Japan | R | Abstract | 20 | 50.0 | 42.9 (20–74)b | NR | 16/NR/NR | Moderate | NR | NR | 4 (20.0) | NR | NR | NR | NR | 6 (30.0) | 8 |
| Ando K et al,29 2021 | Japan | R | Abstract | 71 | NR | NR | NR | NR/NR/NR | NR | NR | NR | 25(35.2) | NR | NR | NR | NR | 27 (38.0) | 8, 16, 32 |
| Dominik E et al,30 2021 | Austria | R | Abstract | 26 | 69.2 | 27 (NR)b | NR | NR/NR/NR | Moderate | NR | NR | NR | NR | NR | NR | NR | NR | 8 |
M: male
R: retrospective
P: prospective
IM: immunomoderator
CS: corticosteroid
TNF: tumor necrosis factor
VED: vedolizumab
TOF: tofacitinib
NR: not reported
a Mean (standard deviation)
b Median (range)
c Median (Interquartile range)